Reata Pharmaceuticals, Inc.
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, includ…
Biotechnology
US, Plano [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q1 | Q2 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | -47.26 | 3.21 | 6.09 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | -382.89 | -1.45 | -0.30 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q1 | Q2 | Δ in % | |
|---|---|---|---|---|
| Book Value | -94.91 | 2.32 | -45.57 | |
| Cash | 0.91 | 8.77 | 8.69 | |
| Capex | -90.59 | < 0.005 | < 0.005 | |
| Free Cash Flow | 15.61 | -1.86 | -2.21 | |
| Revenue | 11340.56 | 0.60 | < 0.005 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q1 | Q2 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | -3.72 | 0.96 | 1.00 | |
| Operating Margin | -98.50 | 8.48 | -566.44 | |
| ROA | 57.26 | 0.38 | -0.24 | |
| ROE | 3260.81 | 2.21 | 0.07 | |
| ROIC | 633.25 | 0.53 | 0.07 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of RETA is permitted for members.
5
Growth
The "Growth Entry" for the Focus of RETA is permitted for members.
6
Leverage & Liquidity